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Diabetes is a major global health problem with over 387 million diabetics causing 4.9 million deaths worldwide. 
Current therapies rely on recombinant insulin injection to the patients several times a day to control glucose 
levels but do not address the fundamental problem; the loss of insulin producing cells of the pancreas. 
Orgenesis developed a cell therapy to replace these cells by taking a small biopsy from a patient’s liver; growing 
the cells in flatware treating; and transdifferentiating these cells with adenovirus vectors containing genes for 
insulin production. This approach allows the diabetic patient to be the donor of their own therapeutic tissue, 
overcoming both the shortage in cadaver tissue availability and immune suppression. To bring this cell therapy 
approach into the pre-clinical and clinical phases, Orgenesis and Pall combined their respective expertise to 
develop a manufacturing strategy for both viral vector and cell products at large scale with the added benefit of 
greater process control incorporating two single-use large scale bioreactors. The Xpansion® 200 single-use 
bioreactor was successfully used to scale-up the human adult liver-derived cells proliferation process. By using 
the Xpansion platform, Orgenesis now has a reliable process to amplify their cells from 10-25 million up to 1.8-2 
billion cells required for curing a diabetic patient. The cell mass generated by the bioreactor preserves their 
viability and potential for trans-differentiation. As a result of this successful co-development partnership, 
Orgenesis is moving forward with their process to large-scale clinical studies for GMP-compliant commercial 
manufacturing of AIP cell for transplantation. For large scale viral production we used the packed-bed iCellis® 
500 disposable bioreactor that provides 3D matrix in a controlled system with low shear stress for adherent 
cells. In this study, we have optimized manufacturing for three adenovirus serotype 5 using the predictive small 
scale iCellis® nano and the manufacture scale iCellis® 500 bioreactor with cultivation area of 66 m2. By 
optimizing culture and infection parameters such as HEK293 cell seeding density, multiplicity of infection, time of 
infection, day of harvest, and media circulation parameters, yield was increased to 5.6x1015 infectious virus 
particle per batch (iCellis 50066). These cells and viral vector yields make the Xpansion® 200 and the iCellis® 
promising scalable technologies for the production of adenovirus products. The purified adenovirus hPDX-1, 
hNeuroD and hMafA were fully functional and successfully transduced the target liver derived cells.  Next step of 





 Figure 1 – Liver cells-based autologous cell therapy schema 
 
